LGALS3 and cancer: Simultaneously, since cancer patients produce autoantibodies to Gal-3 [39], Gal-3 hinders cancer detection/recognition by the endogenous antibodies and/or immunotherapeutic agents, termed the phenomena as “cancer stealth” effect [29].